Evidence map›Paper›PMID 35689481›Full record

ArticleCardiovascular research2023

Regulation and impact of cardiac lymphangiogenesis in pressure-overload-induced heart failure.

Coraline Heron, Anais Dumesnil, Mahmoud Houssari, Sylvanie Renet, Theo Lemarcis, Alexis Lebon, David Godefroy, Damien Schapman, Orianne Henri, Gaetan Riou and 13 more

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Normal cardiac lymphatics and their mimics.American journal of physiology. Heart and circulatory physiology · 2026
    Article
  14. Review
  15. Immunometabolism in heart failure.Nature reviews. Cardiology · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Cardiac lymphatics undergo distinct remodeling during hypertrophic and nonhypertrophic pregnancy.American journal of physiology. Heart and circulatory physiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 2 countries.

Coraline HeronFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.ORCID 0000-0002-3376-0685
Anais DumesnilFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.
Mahmoud HoussariFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.
Sylvanie RenetFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.
Theo LemarcisFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.
Alexis LebonFaculty of Biological Sciences, Normandy University, UniRouen, PRIMACEN, Mont Saint Aignan, France.
David GodefroyFaculty of Biological Sciences, Normandy University, UniRouen, Inserm UMR1239 (DC2N Laboratory), Mont Saint Aignan, France.ORCID 0000-0003-4706-2711
Damien SchapmanFaculty of Biological Sciences, Normandy University, UniRouen, PRIMACEN, Mont Saint Aignan, France.ORCID 0000-0002-8612-8536
Orianne HenriFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.
Gaetan RiouFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1234 (PANTHER Laboratory), Rouen, France.ORCID 0000-0001-5679-9737
Lionel NicolFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.ORCID 0000-0002-7820-4148
Jean-Paul HenryFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.
Manon ValetFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.
Marie Pieronne-DeperroisFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.ORCID 0000-0003-2933-3557
Antoine Ouvrard-PascaudFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.ORCID 0000-0003-1774-0403
Réné HagerlingCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical and Human Genetics, Augustenburger Platz 1, 13353 Berlin, Germany.ORCID 0000-0002-6830-2043
Hélène ChiavelliFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.
Jean-Baptiste MichelUMR 1148, Inserm-Paris University, X. Bichat Hospital, Paris, France.ORCID 0000-0002-1529-2005
Paul MulderFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.ORCID 0000-0002-5936-5704
Sylvain FraineauFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.ORCID 0000-0001-6301-562X
Vincent RichardFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.ORCID 0000-0003-0590-0158
Virginie TardifFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.ORCID 0000-0001-5604-6524
Ebba BrakenhielmFaculty of Pharmacy and Medicine, Normandy University, UniRouen, Inserm (Institut National de la Santé et de la Recherche Médicale) UMR1096 (EnVI Laboratory), FHU CARNAVAL, Rouen, France.ORCID 0000-0003-3378-8300
Inserm · FRHumboldt-Universität zu Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsLymphatics are essential for cardiac health, and insufficient lymphatic expansion (lymphangiogenesis) contributes to development of heart failure (HF) after myocardial infarction. However, the regulation and impact of lymphangiogenesis in non-ischaemic cardiomyopathy following pressure-overload remains to be determined. Here, we investigated cardiac lymphangiogenesis following transversal aortic constriction (TAC) in C57Bl/6 and Balb/c mice, and in end-stage HF patients. METHODS AND

resultsCardiac function was evaluated by echocardiography, and cardiac hypertrophy, lymphatics, inflammation, oedema, and fibrosis by immunohistochemistry, flow cytometry, microgravimetry, and gene expression analysis. Treatment with neutralizing anti-VEGFR3 antibodies was applied to inhibit cardiac lymphangiogenesis in mice. We found that VEGFR3-signalling was essential to prevent cardiac lymphatic rarefaction after TAC in C57Bl/6 mice. While anti-VEGFR3-induced lymphatic rarefaction did not significantly aggravate myocardial oedema post-TAC, cardiac immune cell levels were increased, notably myeloid cells at 3 weeks and T lymphocytes at 8 weeks. Moreover, whereas inhibition of lymphangiogenesis did not aggravate interstitial fibrosis, it increased perivascular fibrosis and accelerated development of left ventricular (LV) dilation and dysfunction. In clinical HF samples, cardiac lymphatic density tended to increase, although lymphatic sizes decreased, notably in patients with dilated cardiomyopathy. Similarly, comparing C57Bl/6 and Balb/c mice, lymphatic remodelling post-TAC was linked to LV dilation rather than to hypertrophy. The striking lymphangiogenesis in Balb/c was associated with reduced cardiac levels of macrophages, B cells, and perivascular fibrosis at 8 weeks post-TAC, as compared with C57Bl/6 mice that displayed weak lymphangiogenesis. Surprisingly, however, it did not suffice to resolve myocardial oedema, nor prevent HF development.

conclusionsWe demonstrate for the first time that endogenous lymphangiogenesis limits TAC-induced cardiac inflammation and perivascular fibrosis, delaying HF development in C57Bl/6 but not in Balb/c mice. While the functional impact of lymphatic remodelling remains to be determined in HF patients, our findings suggest that under settings of pressure-overload poor cardiac lymphangiogenesis may accelerate HF development.

Indexed as

Aortic Valve StenosisHeart FailureAnimalsDisease Models, AnimalEdemaFibrosisHeartLymphangiogenesisMiceMice, Inbred C57BLVentricular RemodelingCCL21HypertrophyInflammationmF4-31C1VegfcVegfdWall stress

Identifiers

PMID35689481
PMCPMC10064842
OpenAlexW4282935551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.